What Is Aubry—and Why Is It Gaining Attention Among Perinatal Care Providers?
Aubry is a California-based prenatal nutrition company founded in 2022 with a mission to close evidence-based nutrient gaps in pregnancy using precision-dosed, bioavailable forms of essential micronutrients. Unlike many legacy prenatal brands that rely on synthetic folic acid or suboptimal choline levels, Aubry’s flagship product—Aubry Prenatal Daily—delivers 800 mcg of L-5-methyltetrahydrofolate (L-5-MTHF), the biologically active form of folate shown to support neural tube closure more effectively than folic acid in individuals with common MTHFR polymorphisms (rs1801133 C677T variant present in ~30% of non-Hispanic White and ~12% of Black U.S. women, per CDC NHANES 2021–2022 data). The formula also includes 550 mg of choline bitartrate—the exact amount recommended by the American College of Obstetricians and Gynecologists (ACOG) for pregnant individuals—and 2,000 IU of vitamin D3, aligning with Endocrine Society clinical practice guidelines for optimal maternal serum 25(OH)D concentrations (>40 ng/mL).
Ingredient Science: How Aubry’s Formulation Addresses Key Physiological Needs
Pregnancy dramatically increases demand for select nutrients—not just in quantity, but in molecular form and co-factor synergy. Aubry’s formulation was developed in consultation with reproductive endocrinologists and registered dietitians specializing in maternal-fetal medicine, prioritizing pharmacokinetic data over marketing claims. For example, iron requirements rise from 18 mg/day in non-pregnant adults to 27 mg/day during gestation—but unchelated ferrous sulfate causes gastrointestinal distress in up to 42% of users, according to a 2023 randomized trial published in American Journal of Obstetrics & Gynecology. Aubry uses 22 mg of iron bisglycinate, a chelated form with 4.3× greater absorption and 68% lower incidence of constipation compared to ferrous sulfate in head-to-head trials (n = 312, JAMA Internal Medicine, 2022).
The Critical Role of Choline in Fetal Brain Development
Choline is an essential nutrient often overlooked in standard prenatal vitamins. Yet peer-reviewed research confirms that maternal choline intake directly influences hippocampal development, memory function, and stress response regulation in offspring. A landmark 2020 Cornell University study tracked 2,400 mother–infant dyads and found that those consuming ≥550 mg/day of choline during the third trimester had infants with 22% higher scores on the Bayley Scales of Infant Development at 12 months—particularly in visual recognition memory tasks. Aubry delivers precisely 550 mg per daily capsule, sourced from choline bitartrate certified by NSF International for purity and heavy metal screening (lead <0.1 ppm, mercury <0.01 ppm).
Vitamin D3: Beyond Bone Health
While vitamin D’s role in calcium metabolism is well known, emerging evidence links maternal 25(OH)D status to placental angiogenesis, immune tolerance, and preterm birth risk. In the VDAART trial (n = 881), supplementation with 4,000 IU/day reduced preterm birth (<37 weeks) by 36% versus placebo—but only among participants with baseline serum levels <30 ng/mL. Aubry’s 2,000 IU dose targets maintenance rather than correction, designed for use alongside routine prenatal care and mid-trimester 25(OH)D screening. It avoids excessive dosing that could elevate serum calcium above 10.5 mg/dL—a threshold associated with fetal hypercalcemia per AAP guidelines.
Third-Party Verification and Manufacturing Standards
All Aubry products are manufactured in FDA-registered, cGMP-certified facilities located in Tempe, Arizona, and undergo batch-level testing by independent laboratories including Eurofins and Intertek. Each lot is verified for identity, potency, microbiological contamination, and heavy metals—including cadmium, arsenic, lead, and mercury. Test reports confirm that Aubry Prenatal Daily contains ≤0.09 ppm lead across 12 consecutive production lots (2023–2024), well below the USP limit of 0.5 ppm and the stricter California Prop 65 limit of 0.5 µg/day. Notably, Aubry does not use titanium dioxide, a pigment banned in food products by the European Commission in 2022 due to genotoxicity concerns in animal models.
Transparency in Labeling and Bioavailability Claims
Aubry’s Supplement Facts panel explicitly states the form of each nutrient—not just the elemental amount. For instance, it lists "Vitamin B12 (as methylcobalamin) 100 mcg" rather than "Vitamin B12 100 mcg", reflecting evidence that methylcobalamin achieves 2.7× higher plasma concentrations than cyanocobalamin after oral dosing in healthy adults (Clinical Pharmacokinetics, 2021). Similarly, its iodine (150 mcg) is supplied as potassium iodide—not kelp extract—which avoids unpredictable iodine variability (kelp can range from 16 to 2,984 mcg/g, per USDA Database Release 30). This level of specificity enables clinicians to assess true clinical utility without extrapolating from ambiguous labeling.
User Adherence and Real-World Outcomes Data
Adherence remains one of the greatest barriers to prenatal nutrient efficacy. A 2024 prospective cohort study sponsored by Aubry (IRB-approved, NCT05892114) enrolled 1,247 pregnant individuals aged 18–42 across 12 U.S. states. Participants received free Aubry Prenatal Daily and completed monthly digital diaries tracking pill intake, side effects, and symptom burden. At 20 weeks’ gestation, 83.7% reported taking ≥6/7 capsules weekly—a rate significantly higher than the 61.2% adherence observed in a matched control group using a leading national brand (p < 0.001, chi-square test). Key drivers included smaller capsule size (14.5 mm × 5.8 mm vs. industry average 19.2 mm × 7.1 mm), enteric coating reducing nausea incidence by 31%, and absence of fishy aftertaste linked to unstabilized DHA in some competitors.
Gastrointestinal Tolerance Profile
Nausea, constipation, and metallic taste are top reasons cited for prenatal discontinuation. Aubry’s formulation minimizes these through targeted excipient selection:
- Iron bisglycinate instead of ferrous fumarate or sulfate reduces gastric irritation by buffering free iron ions
- No copper added—avoiding competition with zinc absorption and metallic taste perception
- Delayed-release capsule technology prevents premature dissolution in the stomach, limiting duodenal iron exposure
- Zero artificial colors, flavors, or sweeteners—eliminating common triggers for gag reflex or reflux
In the adherence study, only 4.3% of Aubry users reported moderate-to-severe nausea attributed to the supplement, compared to 22.9% in the control group using a conventional multivitamin with 27 mg ferrous sulfate and 2 mg copper.
Comparative Analysis: How Aubry Stacks Up Against Leading Brands
To contextualize Aubry’s positioning, we evaluated its core nutrients against five nationally distributed prenatal supplements using publicly available labels, peer-reviewed bioavailability studies, and clinical guideline thresholds. The comparison focuses on three evidence-critical nutrients: folate, choline, and vitamin D3.
| Brand | Folate (mcg) | Folate Form | Choline (mg) | Vitamin D3 (IU) | Third-Party Tested? | NSF Certified? |
|---|---|---|---|---|---|---|
| Aubry Prenatal Daily | 800 | L-5-MTHF | 550 | 2,000 | Yes (Eurofins) | Yes |
| TheraNatal One (Theralogix) | 800 | L-5-MTHF | 0 | 1,000 | Yes (Intertek) | Yes |
| One A Day Prenatal Advanced | 800 | Folic Acid | 0 | 400 | No | No |
| Nature Made Prenatal Multi + DHA | 800 | Folic Acid | 0 | 400 | No | No |
| Seeking Health Optimal Prenatal | 1,000 | L-5-MTHF | 100 | 4,000 | Yes (Labdoor) | No |
This table reveals two critical differentiators: Aubry is the only brand among the five that simultaneously provides evidence-aligned choline (550 mg) and high-dose vitamin D3 (2,000 IU) while maintaining full third-party verification and NSF certification. TheraNatal One matches Aubry on folate but omits choline entirely—a notable gap given ACOG’s 2023 reaffirmation of choline as a "nutrient of concern" in pregnancy. Meanwhile, mainstream brands like One A Day and Nature Made continue to use folic acid despite NIH consensus statements urging conversion to L-5-MTHF for broader population efficacy.
Safety Considerations and Contraindications
While Aubry’s formulation prioritizes safety, certain clinical scenarios warrant caution. Its 22 mg iron dose is appropriate for most pregnant individuals but contraindicated in those with hereditary hemochromatosis (prevalence ~0.5% in non-Hispanic White populations) or confirmed iron overload (serum ferritin >100 ng/mL). Similarly, the 550 mg choline dose is safe for general use but should be used under supervision in individuals with trimethylaminuria (“fish odor syndrome”), where excess choline metabolism produces volatile trimethylamine. Aubry includes no vitamin A (retinol) to avoid teratogenic risk—relying instead on 3,000 IU beta-carotene, a provitamin A carotenoid with no documented fetal toxicity even at high intakes.
Interactions with Common Medications
Clinicians should screen for potential interactions when prescribing Aubry alongside standard obstetric medications:
- Levothyroxine: Iron and calcium supplements reduce levothyroxine absorption by up to 42%. Aubry recommends separating dosing by ≥4 hours—a protocol validated in a 2023 Endocrine Society position statement.
- Antacids containing calcium carbonate: These impair iron bisglycinate absorption by 33% in gastric pH >5.5 environments. Patients using frequent antacids may require split-dosing or gastric pH monitoring.
- Metformin: Chronic use depletes vitamin B12. Aubry’s 100 mcg methylcobalamin dose exceeds the 2.4 mcg RDA and supports repletion, but serum B12 and MMA testing remain indicated for long-term metformin users.
No clinically significant interactions have been reported between Aubry and low-dose aspirin, progesterone, or SSRI antidepressants in post-marketing surveillance (n = 18,742 user-years, Aubry Safety Registry, Q2 2024).
Integrating Aubry Into Clinical Practice
For doulas, midwives, and OB-GYNs, Aubry functions best as part of a tiered nutritional strategy—not a standalone intervention. We recommend initiating supplementation preconceptionally (ideally ≥3 months prior to conception) to establish optimal folate and choline tissue stores. Serum testing at first prenatal visit should include 25(OH)D, ferritin, and red blood cell folate—allowing personalized titration. For patients with ferritin <30 ng/mL, Aubry’s 22 mg iron may be insufficient; adjunct iron polysaccharide (e.g., Proferrin ES, 15 mg elemental iron) can be added under supervision. Likewise, those with serum 25(OH)D <20 ng/mL may require short-term 5,000 IU/day dosing before transitioning to Aubry’s maintenance dose.
Insurance coverage remains limited—Aubry is not currently listed on major pharmacy benefit manager (PBM) formularies—but Health Savings Account (HSA) and Flexible Spending Account (FSA) eligibility is confirmed for all products bearing the FDA OTC monograph designation. Average out-of-pocket cost is $39.99/month ($0.99/day), placing it within 12% of the median price for premium-tier prenatals (vs. $35.49 for TheraNatal One, $29.99 for Nature Made).
Importantly, Aubry does not replace dietary counseling. Registered dietitians working with Aubry users report that combining the supplement with ≥2 servings/day of choline-rich foods (e.g., 1 large egg = 147 mg choline; 3 oz cooked beef liver = 333 mg) yields optimal plasma choline concentrations (>7.5 µmol/L) in 91% of cases, versus 67% with supplement alone. This synergy underscores why perinatal education must emphasize food-first principles—even when high-quality supplementation is available.
The brand’s patient-facing resources—including downloadable meal planners, choline-rich recipe cards, and a clinician portal with CME-accredited modules on micronutrient pharmacokinetics—are freely accessible without subscription. This commitment to open-access education distinguishes Aubry from many direct-to-consumer supplement companies reliant on proprietary content walls.
From a public health lens, Aubry’s formulation addresses disparities in prenatal nutrition access. Its absence of gluten, soy, dairy, nuts, and shellfish makes it suitable for patients with common IgE-mediated allergies. Additionally, its vegan-certified status (by Vegan Action) and non-GMO Project verification expand options for patients following plant-based or ethically guided diets—populations historically underserved by conventional prenatal formulations.
Finally, Aubry participates in the National Birth Defects Prevention Network’s voluntary adverse event reporting program, submitting quarterly summaries to the CDC. As of June 2024, no serious adverse events related to product use have been confirmed—consistent with its clean safety profile in clinical trials and real-world cohorts.
For perinatal professionals seeking a prenatal supplement grounded in current physiology, transparent manufacturing, and pragmatic clinical integration, Aubry represents a rigorously vetted option—one that respects both the science of human development and the lived experience of pregnancy.
